The improved tumoricidal effect of the radioantibody mixture ("cocktail") has been reported recently for the treatment of colon tumor. In the present study, we demonstrated the enhanced radioimmunotherapeutic efficacy of a monoclonal antibody (MAb) cocktail against human hepatocellular carcinoma. Therapeutic efficacy was determined by measuring the change in tumor size over a period, determining the percentage of growth inhibition of each treatment at various times after radioantibody therapy. 
INTRODUCTION
In human, tumor cell populations are heterogeneous in several biochemical and biological properties. Characterization of the antigenic heterogeneity of tumor cell populations may provide an important clue that the mixture ("cocktail") of monoclonal antibodies(MAb) may be required to ensure that all the cells of a tumor could be wiped out [1] . The rationale for using MAb cocktail in tumor radioimmunotherapy has been supported by the results reported previously. An immunohistochemical study using a double-staining technique of the same tissue section indicates that a greater number of cancer cells can be detected when both anti-carcinoembryonic antigen antibodies and anti-TAG-72 antibodies are used in combination [2] . Improved radioimmunotherapy of GW-39 human colorectal cancer xenografts using the MAb cocktail against carcinoembryonic antigen and colon-specific antigen-p has also been shown [3] . In this paper, we evaluate the therapeutic efficacy of the MAb cocktail in a human hepatoma xenograft model, and demonstrate the advantage of mixing MAbs recognizing different epitopes in the treatment of human hepatocellular carcinoma.
MATERIALS AND METHODS

Materials
RPMI 1640, Gibco; fluorescein isothiocyanate (FITC), Sigma; mouse MAb isotyping kit, Sigma; sephadex-25, Sigma; SDS-PAGE high and low molecular weight markers for proteins, Sigma; goat anti-mouse IgG peroxidase conjugate, Sigma; iodogen (chloramine-1, 3, 4, 6-tetrachloro -3, 6-diphenylglycoluril) 
Competitive binding assay by flow cytometry
Competitive binding assay was performed to determine whether MAb Hepama-a and 9403 recognized different antigenic determinats according to the method reported previously [2] . MAb 9403 was tested for its ability to compete for the binding to hepatoma cells with FITC-Hepama-1. Frist, SMMC-7721 cells were put into five different test tubes, then saturated amount of MAb 9403, Hepama-1 and OKT3 were added seperately in to each of test tubes and incubated for 45 min at 4 ℃, finally FITC-Hepama-1 was added seperately to these three test tubes and incubated again for 45 min at 4 ℃, the amount of bound FITC-antibody was determined as percentage of positive cells as measured by flow cytometry. OKT3 antibody was used here as control for competitive binding and the remaining two tubes with FITC-mouse IgG and FITC-Hepama-1 were served as values for blank control and control for normal FITC-Hepama-1 binding.
Western blot analysis
The total protein of SMMC-7721 cells was separated by 10% PAGE, transferred to Hybond C nitrocellulose membrane (Amersham), and then hybridized with MAbs according to the conventional method.
Human hepatoma xenograft model Subsequent measurements of tumor size were compared to the initial measurement, and the average change in size was recorded over a period [3] . When the experiments were ended, all animals were sacrificed by cervical dislocation.
Statistics
The statistical significance of differences (P<0.05) was determined using the Student's t-test
RESULTS AND DISCUSSION
As shown in Fig 1, Another possible reason for the improved tumoricidal effect of the MAb cocktail is that the mixture targets more antigen epitopes on individual tumor cells. Different fluorescence intensities on individual human hepatoma cells treated with Mabs were determined by flow cytometry in vitro (Fig 2) . Tumor cell uptake of 1.5 μM of each antibody in combination (Fig 2 D) was 69% higher than the uptake of 1.5 μM Hepama-1 alone (Fig 2 B) and 23% higher than the uptake of 1.5 μM 9403 alone (Fig 2 C) . This increased uptake of the MAb cocktail by hepatoma cells may be associated with recognizing distinct epitopes on tumor cells. To determine whether MAb Hepama-1 and 9403 bound the same antigen determinants, competitive binding analysis was performed using FITC-MAbs and unlabeled-MAbs. Unlabeled-Hepama-1 competed with FITC-Hepama-1, whereas unlabeled-9403 did not compete with FITC-Hepama-1 (Tab 3). It demonstrated that MAb Hepama-1 and 9403 recognized different epitopes on the human hepatoma cells. This result was further supported by Western blot analysis (Fig 3) . Under the same conditions, MAb Hepama-1 was shown to be reactive with a 43 k Da molecule (Fig 3 A) , but MAb 9403 gave no antigen band (Fig 3 B) , further suggesting that antigenic determinants recognized by the above mentioned two MAbs are different. In summary, in view of the degree of antigenic heterogeneity which has been observed in human hepatocellular carcinoma, we have improved the radioimmunotherapy by using a MAb cocktail that targets a greater number of human hepatoma cells and different epitopes on the same cell. However, further studies are still needed to 
